TG Therapeutics to Participate in H.C. Wainwright 28th Annual Global Investment Conference

TG Therapeutics' CEO will speak at the H.C. Wainwright Conference on September 14, 2026, with a live webcast available.

Quiver AI Summary

TG Therapeutics, Inc. announced that Michael S. Weiss, the Chairman and CEO, will participate in the H.C. Wainwright 28th Annual Global Investment Conference from September 14-16, 2026, with a fireside chat scheduled for September 14 at 12:00pm ET. Investors can access the live webcast on the company's website. TG Therapeutics is a biotechnology firm dedicated to developing treatments for B-cell diseases and has received FDA approval for its drug BRIUMVI® (ublituximab-xiiy) for adult patients with relapsing forms of multiple sclerosis, among other global approvals. More details can be found on the company’s website and social media platforms.

Potential Positives

Participation of CEO Michael S. Weiss in a prominent investment conference highlights the company's engagement with the investment community and could enhance visibility and investor interest.
The scheduled fireside chat provides a platform for the company to share updates and insights on its pipeline and growth prospects, potentially attracting new investors.
Approval from the FDA for BRIUMVI® (ublituximab-xiiy) establishes TG Therapeutics as a key player in the treatment of multiple sclerosis, reinforcing its reputation and market position in a specialized therapeutic area.
International approvals for BRIUMVI further strengthen the company's global presence and market opportunities beyond the U.S.

Potential Negatives

Participants may perceive the participation in the conference as a response to pressure for visibility amidst concerns about the company's long-term growth prospects.
The timing of the conference may coincide with ongoing challenges in the biopharmaceutical sector, potentially overshadowing positive developments.
Relevant financial or operational challenges were not addressed in the release, leaving stakeholders with unanswered questions about the company's stability and future plans.

FAQ

What event will TG Therapeutics participate in?

TG Therapeutics will participate in the H.C. Wainwright 28th Annual Global Investment Conference from September 14-16, 2026.

Who from TG Therapeutics will speak at the conference?

Michael S. Weiss, the Chairman and CEO of TG Therapeutics, will participate in the fireside chat.

When is the fireside chat scheduled?

The fireside chat is scheduled for Monday, September 14, 2026, at 12:00pm ET.

How can I watch the fireside chat?

A live webcast of the fireside chat will be available on the Events page of TG Therapeutics' website.

What is BRIUMVI® approved for?

BRIUMVI® is FDA-approved to treat adult patients with relapsing forms of multiple sclerosis.

Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.

$TGTX Revenue

$TGTX had revenues of $240.3M in Q2 2026. This is an increase of 70.27% from the same period in the prior year.

You can track TGTX financials on Quiver Quantitative's TGTX stock page.

You can access data on TGTX stock through the Quiver Quantitative API.

$TGTX Hedge Fund Activity

We have seen 251 institutional investors add shares of $TGTX stock to their portfolio, and 183 decrease their positions in their most recent quarter.

Here are some of the largest recent moves:

D. E. SHAW & CO., INC. added 2,700,463 shares (+385.6%) to their portfolio in Q2 2026, for an estimated $148,363,437
PRICE T ROWE ASSOCIATES INC /MD/ added 2,134,922 shares (+337.4%) to their portfolio in Q2 2026, for an estimated $117,292,614
SIXTH STREET PARTNERS MANAGEMENT COMPANY, L.P. added 1,313,103 shares (+inf%) to their portfolio in Q2 2026, for an estimated $72,141,878
SOLEUS CAPITAL MANAGEMENT, L.P. removed 1,101,424 shares (-27.3%) from their portfolio in Q2 2026, for an estimated $60,512,234
TWO SIGMA INVESTMENTS, LP added 926,659 shares (+60.1%) to their portfolio in Q2 2026, for an estimated $50,910,645
CITADEL ADVISORS LLC added 911,852 shares (+90.2%) to their portfolio in Q1 2026, for an estimated $30,291,723
STATE STREET CORP removed 863,295 shares (-10.0%) from their portfolio in Q2 2026, for an estimated $47,429,427

To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.

$TGTX Price Targets

Multiple analysts have issued price targets for $TGTX recently. We have seen 2 analysts offer price targets for $TGTX in the last 6 months, with a median target of $45.0.

Here are some recent targets:

Alec Stranahan from B of A Securities set a target price of $20.0 on 07/07/2026
Emily Bodnar from HC Wainwright & Co. set a target price of $70.0 on 07/06/2026

Full Release

NEW YORK, Sept. 10, 2026 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX) today announced that Michael S. Weiss, the Company’s Chairman and Chief Executive Officer, will participate in the H.C. Wainwright 28 ^th Annual Global Investment Conference, being held on September 14 - 16, 2026. The fireside chat is scheduled to take place on Monday, September 14, 2026, at 12:00pm ET.

A live webcast of the fireside chat will be available on the Events page, located within the Investors & Media section, of the Company’s website at http://ir.tgtherapeutics.com/events .

ABOUT TG THERAPEUTICS
TG Therapeutics is a fully integrated, commercial stage, biotechnology company focused on the acquisition, development and commercialization of novel treatments for B-cell diseases. In addition to a research pipeline, TG Therapeutics has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI ^® (ublituximab-xiiy) to treat adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, as well as approval from several regulatory agencies outside of the U.S. for BRIUMVI to treat adult patients with RMS who have active disease defined by clinical or imaging features. For more information, visit www.tgtherapeutics.com , and follow us on X (formerly Twitter) @TGTherapeutics and on LinkedIn .

BRIUMVI ^® is a registered trademark of TG Therapeutics, Inc.

CONTACT:

Investor Relations
Email: [email protected]
Telephone: 1.877.575.TGTX (8489), Option 4

Media Relations:
Email: [email protected]
Telephone: 1.877.575.TGTX (8489), Option 6